STOCK TITAN

Vertex to Announce First Quarter 2024 Financial Results on May 6

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2024 financial results on May 6, 2024, after the market closes. A conference call and webcast will follow at 4:30 p.m. ET. Participants can access the call by dialing (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and mentioning 'Vertex Pharmaceuticals First Quarter 2024 Earnings Call.' The webcast link will be available on Vertex's website. Registration 15 minutes before the webcast is advised.
Positive
  • None.
Negative
  • None.

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals First Quarter 2024 Earnings Call.”

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, autosomal dominant polycystic kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

(VRTX-WEB)

Vertex Pharmaceuticals Incorporated Investor Relations:

investorinfo@vrtx.com

Source: Vertex Pharmaceuticals Incorporated

FAQ

When will Vertex Pharmaceuticals (VRTX) announce its first quarter 2024 financial results?

Vertex Pharmaceuticals (VRTX) will announce its first quarter 2024 financial results on May 6, 2024, after the market closes.

How can participants access the conference call for Vertex Pharmaceuticals (VRTX) first quarter 2024 earnings?

Participants can access the conference call by dialing (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and mentioning 'Vertex Pharmaceuticals First Quarter 2024 Earnings Call.'

Where can the webcast link for the Vertex Pharmaceuticals (VRTX) first quarter 2024 earnings call be found?

The webcast link will be available on Vertex's website at www.vrtx.com in the 'Investors' section.

Is it recommended to register before the scheduled webcast for Vertex Pharmaceuticals (VRTX) first quarter 2024 earnings?

Yes, it is recommended to register at least 15 minutes prior to the scheduled webcast to ensure a timely connection.

Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Stock Data

118.29B
257.53M
0.09%
95.96%
1.66%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON